Syndax and Merck announce first patients dosed in phase Ib/II clinical trial of entinostat and Keytruda

Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma.

“This is an important clinical milestone for Syndax and our collaboration with Merck that was achieved on schedule with our joint development plan,” said Michael L. Meyers, Syndax’s Chief Development Officer. “As entinostat has been shown in preclinical models to reduce the number and inhibit the function of host immune suppressor cells, we believe that entinostat combined with Keytruda could result in an improved response rate for the combination compared to either agent alone. The initiation of this trial advances our immuno-oncology program developing entinostat as a potential combination therapy in multiple cancer indications with an initial focus on tumours that have shown sensitivity to immunotherapy.”

“Our collaboration with Syndax exemplifies our interest in exploring innovative therapeutic combinations with Keytruda,” said Eric Rubin, vice president and therapeutic area head, early-stage oncology development, Merck Research Laboratories. “We are pleased with the rapid initiation and progress being made by Syndax towards gaining a better understanding of the potential of Keytruda and entinostat in these difficult-to-treat patient populations.” The ENCORE 601/KEYNOTE 142 trial is designed as a Phase Ib/II open label clinical trial with dose escalation for entinostat, in which the Phase Ib portion will evaluate the safety and tolerability of the combination of entinostat and Keytruda in patients with NSCLC, and the Phase II portion will assess the safety and preliminary efficacy of the combination in separate cohorts in patients with NSCLC or melanoma. The trial will be conducted in the US and is expected to enroll up to 178 patients.